维普中文期刊产品整合服务
9篇 您的检索式:作者名="Kristeleit"
    题名 作者 年代 出处 被引量
1Homologous recombination deficiency and ovarian cancer 显示文摘Ledermann J A Drew Y Kristeleit R S 2016Eur J Cancer2016,60,:1
2Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis 显示文摘Kristeleit R Swisher E Oza A 2015Eur J Cancer2015,15,3:1
3Histone modification enzymes: novel targets for cancer drugs 显示文摘Kristeleit R Stimson L Workman P Aheme W 2004Expert Opin Emerg Drugs2004,9,:1
4A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitorGDC-0941显示文摘Baird R Kristeleit R Sarker D 0,,02:1
5A phase I study of quisinostat (JNJ-26481585) , an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and anti- tumor activity, in patients with advanced solid tumors 显示文摘Venugopal B Baird R Kristeleit RS 2013Clin Cancer Res2013,19,15:1
6Histone modification enzymes : novel targets for cancer drugs 显示文摘Kristeleit R Stimson L Workman P 2004Expert Opin Emerg Drugs2004,9,1:1
7Systemic treatment of non- small-cell lung cancer 显示文摘Lal R Enting D Kristeleit H 2011Eur J Cancer2011,47,3:1
8Phase I study to determine the safety,toler ability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers显示文摘Bartlett J B Michael A Clarke I A Dredge K Nicholson S Kristeleit H 2004Br J Cancer2004,90,:1
9A Phase Ⅰ Study of Quisinostat (JNJ-26481585),an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity,in Patients with Advanced Solid Tumors显示文摘Venugopal B Baird R Kristeleit RS 0,,15:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费